Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Resulting from the merger of BioAlliance Pharma (France) and Topotarget (Denmark) in July 2014, Onxeo is a new leader in European biotechnology. Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. Through bringing pioneering drugs to market, the company wants to improve patients’ lives, fund continuous investment in R&D of orphan diseases, and create value for all company’s stakeholders and shareholders. It has three strategic programs in advanced development and two products already registered in the European and US markets, demonstrating its teams’ expertise and know-how.
49 boulevard du Général Martial Valin
75015 PARIS, France
Tel: +33 (0)1 45 58 76 00
Fax: +33 (0)1 45 58 08 81
Investors: investors@onxeo.com
Email: contact@onxeo.com
Website: www.onxeo.com
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device…
Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014:…
While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research.…
Olivier Laureau, President of the Servier Group, discusses how Servier´s economic model is based on considerable investments in R&D to provide for a better future and on a strong international…
Stéphane Thiroloix, CEO of the independent and family owned Mayoly Spindler, reveals how their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics; how…
Jean-Charles Foddis, executive director of Aderly, Lyon’s main investment agency, discusses the city’s history of economic development while highlighting its main strengths and challenges for the future in life sciences.…
Amatsigroup, a Contract Development and Manufacturing Organization (CDMO), provides services throughout both preclinical and clinical phases. Leading over 200 highly qualified employees with a portfolio of over 300 clients, President…
Providing an all-in-one venue for major corporate conference, seminar, or gala events, Disney Business Solutions at Disneyland Paris provides customized services to meet all clients’ needs. Director Nicolas Dupeux shares…
André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution;…
Serving as the leader of two companies – Platine, a CRO, and Indicia, a CMO – Stephane Legastelois, in his own words, challenges himself by wearing two different hats. Offering…
Laurence Comte-Arassus, president of Medtronic France, reveals how after the global acquisition of Covidien in January 2015, France is now their second largest subsidiary in the EMEA region; how Medtronic´s…
Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell…
See our Cookie Privacy Policy Here
